Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
10/06/2020 10/07/2020 10/08/2020 10/09/2020 10/12/2020 Date
34.42 34.43 34.43 34.59 34.49 Last
1008384 1143123 762768 4557258 987254 Volume
-0.06% +0.03% 0.00% +0.46% -0.29% Change
Financials (USD)
Sales 2018 - - -
Net income 2018 -211 M - -
Net cash position 2018 304 M - -
P/E ratio 2018 -6,52x
Yield 2018 -
Sales 2019 - - -
Net income 2019 -248 M - -
Net cash position 2019 89,6 M - -
P/E ratio 2019 -8,43x
Yield 2019 -
Capitalization 2 268 M 2 268 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 339
Free-Float 77,8%
More Financials
Company
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT.... 
More about the company
All news about AIMMUNE THERAPEUTICS, INC.
01/22AIMMUNE THERAPEUTICS : European Commission approves Aimmune's PALFORZIA as first..
AQ
01/05AIMMUNE THERAPEUTICS : European Commission approves first treatment for peanut a..
AQ
2020AIMMUNE THERAPEUTICS : European Commission approves Aimmune's PALFORZIA as first..
AQ
2020AIMMUNE THERAPEUTICS : European Commission Approves Aimmune's PALFORZIA® as Firs..
BU
2020Chinook Therapeutics Names Eric Bjerkholt Chief Financial Officer
MT
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
AQ
2020AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
AQ
2020MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
2020AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
2020AIMMUNE THERAPEUTICS : Nestle announces results of tender offer for Aimmune Ther..
AQ
2020GLOBAL MARKETS LIVE: U.S. banks beat expectations
2020Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With S..
DJ
2020AIMMUNE THERAPEUTICS : shareholders accept $2 billion Nestle tender offer
RE
2020Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
PR
More news
News in other languages on AIMMUNE THERAPEUTICS, INC.
2020Bourse Zurich: la nouvelle variante du coronavirus effraie le marché
2020Bourse Zurich: toujours plombée par les craintes sur la nouvelle souche de vi..
2020Bourse Zurich: les craintes sur la nouvelle souche de virus l'emportent
2020Nestlé fait une percée pour traiter l'allergie aux arachides
2020Bourse Zurich: la mutation du coronavirus effraie les investisseurs
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.0.00%2 268
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148